Aktie A195940 HK INNO.N CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen HK inno.N Corporation

Aktien

A195940

KR7195940002

A195940

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
38’750 KRW -1.27% Intraday Chart für HK inno.N Corporation +2.51% -12.82%
2022 Sebela Pharmaceuticals® erwirbt exklusive Lizenzrechte von HK inno.N Corporation zur Entwicklung und Vermarktung von Tegoprazan in den USA und Kanada CI
2022 Sebela Pharmaceuticals geht eine exklusive Partnerschaft mit HK inno.N Corporation ein CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.
HK inno.N Corporation authorizes a Buyback Plan.
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.
HK inno.N Corporation has filed an IPO.
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A195940 Aktie
  4. Nachrichten HK inno.N Corporation
  5. Andere Sprachen